Drugs / rhIGF-1/rhIGFBP-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02386839 | Mar 2015 → Sep 2021 | retinopathy of prematurity | Shire | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-06-30 | Takeda | Results Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants takeda.com ↗
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that its Phase 2 study evaluating an investigational protein replacement, SHP607, did not meet its primary endpoint of reducing the severity of retinopathy of prematurity (ROP), a rare eye condition. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-06-30 | Takeda | Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants takeda.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhIGF-1/rhIGFBP-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02386839 ↗ |